ПЕРВИЧНЫЙ АЛЬДОСТЕРОНИЗМ И РЕЗИСТЕНТНАЯ АРТЕРИАЛЬНАЯ ГИПЕРТЕНЗИЯ
https://doi.org/10.18705/1607-419X-2012-18-6-514-521
Аннотация
В обзорной статье обсуждаются новые данные по первичному альдостеронизму, а также связь между повышением уровня альдостерона и резистентной артериальной гипертензией, в том числе и у пациентов с синдромом обструктивного апноэ во сне. Рассматриваются основные патофизиологические механизмы, лежащие в основе прогрессирования поражения органов-мишеней и формирования резистентности к антигипертензивной терапии при повышении уровня альдостерона.
Об авторах
Н. Э. Звартау
ФГБУ «Федеральный Центр сердца, крови и эндокринологии им. В.А. Алмазова» Минздрава России
Россия
Россия
Л. С. Коростовцева
ФГБУ «Федеральный Центр сердца, крови и эндокринологии им. В.А. Алмазова» Минздрава России
Россия
Россия
И. В. Емельянов
ФГБУ «Федеральный Центр сердца, крови и эндокринологии им. В.А. Алмазова» Минздрава России
Россия
Россия
Ю. В. Свиряев
ФГБУ «Федеральный Центр сердца, крови и эндокринологии им. В.А. Алмазова» Минздрава России
Россия
Россия
Список литературы
1. Funder J.W., Carey R.M., Fardella C. et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline // J. Clin. Endocrinol. Metab. - 2008. - Vol. 93, № 9. - Р. 3266–3281.
2. Lim P., Dow E., Brennan G., Jung R.T., MacDonald T.M. High prevalence of primary aldosteronism in the Tayside hypertension clinic population // J. Hum. Hypertens. - 2000. – Vol. 14, № 5. – P. 311–315.
3. Loh K., Koay E., Khaw M., Emmanuel S.C., Young W.F. Jr. Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore // J. Clin. Endocrinol. Metab. - 2000. – Vol. 85. № 8. – P. 2854–2859.
4. Mosso L., Carvajal C., Gonzalez A. et al. Primary aldosteronism and hypertensive disease // Hypertension. – 2003. – Vol. 42, № 2. – P. 161–165.
5. Rossi G., Bernini G., Caliumi C. et al. A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients // J. Am. Coll. Cardiol. – 2006. – Vol. 48, № 11. - P. 2293–2300.
6. Schwartz G., Turner S. Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity // Clin. Chem. – 2005. – Vol. 51, № 2. – P. 386–394.
7. Ito Y., Takeda R., Karashima S. et al. Prevalence of primary aldosteronism among prehypertensive and stage 1 hypertensive subjects // Hypertens. Res. – 2011. – Vol. 34, № 1. – P. 98–102.
8. Calhoun D.A. Is there an unrecognized epidemic of primary aldosteronism? (Pro) // Hypertension. – 2007. – Vol. 50, № 3. – P. 447–453.
9. Sukor N., Kogovsek C., Gordon R., Robson D., Stowasser M. Improved quality of life, blood pressure, and biochemical status following laparoscopic adrenalectomy for unilateral primary aldosteronism // J. Clin. Endocrinol. Metab. – 2010. – Vol. 95, № 3. – P. 1360–1364.
10. Rossi G., Seccia T., Pessina A. et al. Primary aldosteronism — part I: prevalence, screening, and selection of cases for adrenal vein sampling // J. Nephrol. – 2008. – Vol. 21, № 4. – P. 447–454.
11. Douma S., Petidis K., Doumas M. et al. Prevalence of primary hyperaldosteronism in resistant hypertension:a retrospective observational study // Lancet. – 2008. – Vol. 371, № 9628. – P. 1921–1926.
12. Nishizaka M. K., Zaman M. A., Calhoun D. A. Efficacy of low-dose spironolactone in subjects with resistant hypertension // Am. J. Hypertens. – 2003. - Vol. 16, № 11. - P. 925–930.
13. Vasan R. S., Evans J. C., Larson M. G. et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons // N. Engl. J. Med. – 2004. - Vol. 351, № 1. – P. 33–41.
14. Bernini G., Galetta F., Franzoni F. et al. Arterial stiffness, intima-media thickness and carotid artery fibrosis in patients with primary aldosteronism // J. Hypertens. – 2008. - Vol. 26, № 12. – P. 2399–2405.
15. Tsuchiya K., Yoshimoto T., Hirata Y. Endothelial dysfunction is related to aldosterone excess and raised blood pressure // Endocrine J. – 2009. - Vol. 56, № 4. - P. 553–559.
16. Tsioufis C., Tsiachris D., Dimitriadis K. et al. Myocardial and aortic stiffening in the early course of primary aldosteronism // Clin. Cardiol. – 2008. - Vol. 31, № 9. - P. 431–436.
17. Rossi G. P., Bernini G., Desideri G. et al. Renal damage in primary aldosteronism: results of the PAPY study // Hypertension. – 2006. - Vol. 48, № 2. – P. 232–238.
18. Milliez P., Girerd X., Plouin P. et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism // J. Am. Coll. Cardiol. - 2005. – Vol. 45, № 8. – P. 1243–1248.
19. Stowasser M. Sharman J., Leano R. et al. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I // J. Clin. Endocrinol. Metab. – 2005. – Vol. 90, № 9. – P. 5070–5076.
20. McAdam-Marx C., Ye X., Sung J. C.,. Brixner D. I. et al. Results of a retrospective, observational pilot study using electronic medical records to assess the prevalence and characteristics of patients with resistant hypertension in an ambulatory care setting // Clin. Ther. – 2009. - Vol. 31, № 5. – P. 1116–1123.
21. Logan A. G., Perlikowski S. M., Mente A. et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension // J. Hypertens. – 2001. - Vol. 19, № 12. – P. 2271–2277.
22. Cuspidi C., Macca G., Sampieri L. et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension // J. Hypertens. – 2001. - Vol. 19, № 11. – P. 2063–2070.
23. Muxfeldt E. S., Bloch K. V., Nogueira A. R. et al. Twenty-four hour ambulatory blood pressure monitoring pattern of resistant hypertension // Blood Pres. Monitor. – 2003. - Vol. 8, № 5. – P. 181–185.
24. Pierdomenico S. D., Lapenna D., Bucci A. et al. Cardiovascular outcome in treated hypertensive patients with responder, masked, false resistant, and true resistant hypertension // Am. J. Hypertens. – 2005. - Vol. 18, № 11. – P. 1422–1428.
25. Isaksson H., Ostergren J. Prognosis in therapy-resistant hypertension // J. Int. Med. – 1994. - Vol. 236, № 6. – P. 643–649.
26. Pratt-Ubunama M. N., Nishizaka M. K., Boedefeld R. L. et al. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension // Chest. – 2007. - Vol. 131, № 2. – P. 453–459.
27. Lavie P., Hoffstein V. Sleep apnea syndrome: a possible contributing factor to resistant // Sleep. – 2001. - Vol. 24, № 6. - P. 721–725.
28. Dernaika T.A., Kinasewitz G.T., Tawk M.M. Effects of nocturnal continuous positive airway pressure therapy in patients with resistant hypertension and obstructive sleep apnea // J. Clin. Sleep Med. – 2009. - Vol. 5, № 2 - P. 103–107.
29. Lozano L., Tovar J. L., Sampol G. et al. Continuous positive airway pressure treatment in sleep apnea patients with resistant hypertension: a randomized, controlled trial // J. Hypertens. – 2010. - Vol. 28, № 10. – P. 2161–2168.
30. Di Murro A., Petramala L., Cotesta D. et al. Renin-angiotensin-aldosterone system in patients with sleep apnoea: prevalence of primary aldosteronism // J. Renin Angiotensin Aldosterone Syst. – 2010. - Vol. 11, № 3. – P. 165–172.
31. Acelajado M.C., Calhoun D.A. Aldosteronism and resistant hypertension // Int. J. Hypertens. – 2011. – Vol. 2011. - Article ID 837817. doi: 10.4061/2011/837817.
32. Gaddam K., Pimenta E., Thomas S. et al. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report // J. Hum. Hypertens. – 2010. – Vol. 24, № 8. – P. 532–537.
33. Funder J.W. Mineralocorticoid receptors: distribution and activation // Heart Failure Rev. - 2005. – Vol. 10, № 1. – P. 15–22.
34. Boldyreff B., Wehling M. Aldosterone: refreshing a slow hormone by swift action // News Physiol. Sci. – 2004. – Vol. 19. – P. 97–100.
35. Liu S.L., Schmuck S., Chorazcyzewski J.Z., Gros R., Feldman R.D. Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation // Circulation. – 2003. – Vol. 108, № 19. – P. 2400–2406.
36. Uhrenholt T. R., Schjerning J., Hansen P. B. et al. Rapid inhibition of vasoconstriction in renal afferent arterioles by aldosterone // Circ. Res. – 2003. – Vol. 93, № 12. – P. 1258–1266.
37. Arima S., Kohagura K., Xu H.L. et al. Endothelium-derived nitric oxide modulates vascular action of aldosterone in renal arteriole // Hypertension. – 2004. – Vol. 43, № 2. – P. 352–357.
38. Michea L., Delpiano A. M., Hitschfeld C., Lobos L., Lavandero S., Marusic E.T. Eplerenone blocks nongenomic effects of aldosterone on the Na+/H+-exchanger, intracellular Ca2+ levels, and vasoconstriction in mesenteric resistance vessels // Endocrinology. – 2005. – Vol. 146, № 3. – P. 973–980.
39. Rocha R., Stier C.T.J., Kifor I. et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy // Endocrinology. – 2000. – Vol. 141, № 10. – P. 3871–3878.
40. Sun Y., Zhang J., Lu L., Bedigian M.P., Robinson A.D., Weber K.T. Tissue angiotensin II in the regulation of inflammatory and fibrogenic components of repair in the rat heart // J. Lab. Clin. Med. – 2004. – Vol. 143, № 1. – P. 41–51.
41. Brilla C.G., Weber K.T. Mineralocorticoidexcess, dietary sodium, and myocardial fibrosis // J. Lab. Clin. Med. – 1992. – Vol. 120, № 6. – P. 893–901.
42. Rocha R., Martin-Berger C.L., Yang P. et al. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart // Endocrinology. – 2002. – Vol. 143, № 12. – P. 4828–4836.
43. Rocha R., Chander P.N., Khanna K., Zuckerman A., Stier C.T. Jr. Mineralocorticoid blockadereduces vascular injury in stroke-prone hypertensive rats // Hypertension. – 1998. – Vol. 31, № 1, Pt. 2. – P. 451–458.
44. Han S.Y., Kim C.H., Kim H.S. et al. Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats // J. Am. Soc. Nephrol. – 2006. – Vol. 17, № 5. – P. 1362–1372.
45. Chun T.Y., Bloem L.J., Pratt J.H. Aldosterone inhibits inducible nitric oxide synthase in neonatal rat cardiomyocytes // Endocrinology. – 2003. – Vol. 144, № 5. – P. 1712–1717.
46. Wahed M.I., Watanabe K., Ma M. et al. Effects of eplerenone, a selective aldosterone blocker, on the progression of left ventricular dysfunction and remodeling in rats with dilated cardiomyopathy // Pharmacology. – 2005. – Vol. 73, № 2. – P. 81–88.
47. Rocha R., Rudolph A.E., Frierdich G.E. et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart // Am. J. Physiol. Heart Circ. Physiol. – 2002. – Vol. 283, № 5. - H1802–H1810.
48. Okada H., Danoff T.M., Kalluri R., Neilson E.G. Early role of Fsp1 in epithelial-mesenchymal transformation // Am. J. Physiol. – 1997. – Vol. 273, № 4, Pt. 2. – P. F563–F574.
49. Ma L.J., Yang H., Gaspert A. et al. Transforming growth factor-β-dependent and -independent pathways of induction of tubulointerstitial fibrosis in β6−/− mice // Am. J. Pathol. – 2003. – Vol. 163, № 4. – P. 1261–1273.
50. Park J.B., Schiffrin E.L. Cardiac and vascular fibrosis and hypertrophy in aldosterone-infused rats: role of endothelin-1 // Am. J. Hypertens. – 2002. – Vol. 15, № 2, Pt. 1. – P. 164–169.
51. Wong S., Brennan F.E., Young M.J. et al. A direct effect of aldosterone on endothelin-1 gene expression in vivo // Endocrinology. – 2007. – Vol. 148, № 4. – P. 1511–1517.
52. Guarda E., Katwa L.C., Myers P.R., Tyagi S.C., Weber K.T. Effects of endothelins on collagen turnover in cardiac fibroblasts // Cardiovasc. Res. – 2003. – Vol. 27, № 12. – P. 2130–2134.
53. Tostes R.C., Touyz R.M., He G., Ammarguellat F., Schiffrin E.L. Endothelin A receptor blockade decreases expression of growth factors and collagen and improves matrix metalloproteinase-2 activity in kidneys from stroke-prone spontaneously hypertensive rats // J. Cardiovasc. Pharmacol. – 2002. – Vol. 39, № 6. – P. 892–900.
54. Pu Q., Neves M. F., Virdis A. et al. Endothelin antagonism on aldosterone-induced oxidative stress and vascular remodeling // Hypertension. – 2003. – Vol. 42, № 1. – P. 49–55.
55. Taddei S., Virdis A., Mattei P., Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension // Hypertension. – 1993. – Vol. 21, № 6, Pt. 2. – P. 929–933.
56. Nishizaka M.K., Zaman M.A., Green S.A., Renfroe K.Y., Calhoun D.A. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism // Circulation. – 2004. – Vol. 109, № 23. – P. 2857–2861.
57. Farquharson C.A., Struthers A.D. Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy // Clin. Sci. (Lond.). – 2002. – Vol. 103, № 4. – P. 425–431.
58. Romagni P., Rossi F., Guerrini L., Quirini C., Santiemma V. Aldosterone induces contraction of the resistance arteries in man // Atherosclerosis. – 2003. – Vol. 166, № 2. – P. 345–349.
59. Farquharson C.A., Struthers A.D. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure // Circulation. – 2002. – Vol. 101, № 6. – P. 594–597.
60. Iglarz M., Touyz R.M., Viel E.C., Amiri F., Schiffrin E.L. Involvement of oxidative stress in the profibrotic action of aldosterone. Interaction with the renin-angiotensin system // Am. J. Hypertens. – 2004. – Vol. 17, № 7. - P. 597–603.
61. Blanco-Rivero J., Cachofeiro V., Lahera V. et al. Participation of prostacyclin in endothelial dysfunction induced by aldosterone in normotensive and hypertensive rats // Hypertension. – 2005. – Vol. 46, № 1. - P. 107–112.
62. Calo L. A., Zaghetto F., Pagnin E. et al. Effect of aldosterone and glycyrrhetinic acid on the protein expression of PAI-1 and p22phox in human mononuclear leukocytes // J. Clin. Endocrinol. Metab. – 2004. – Vol. 89, № 4. – P. 1973–1976.
63. Chun T.Y., Pratt J.H. Aldosterone increases plasminogen activator inhibitor-1 synthesis in rat cardiomyocytes // Mol. Cell. Endocrinol. – 2005. – Vol. 239, № 1-2. – P. 55–61.
64. Fejes-Tóth G., Náray-Fejes-Tóth A. Early aldosterone-regulated genes in cardiomyocytes: clues to cardiac remodeling? // Endocrinology. – 2007. – Vol. 148, № 4. – P. 1502–1510.
65. Oestreicher E.M., Martinez-Vasquez D., Stone J.R. et al. Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-l-arginine methyl ester-induced myocardial injury // Circulation. - 2003. – Vol. 108, № 20. – P. 2517–2523.
66. Wang W. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog // Hypertension. – 1994. – Vol. 24, № 5. – P. 571-575.
Рецензия
Для цитирования:
Звартау Н.Э., Коростовцева Л.С., Емельянов И.В., Свиряев Ю.В. ПЕРВИЧНЫЙ АЛЬДОСТЕРОНИЗМ И РЕЗИСТЕНТНАЯ АРТЕРИАЛЬНАЯ ГИПЕРТЕНЗИЯ. Артериальная гипертензия. 2012;18(6):514-521. https://doi.org/10.18705/1607-419X-2012-18-6-514-521
For citation:
Zvartau N.E., Korostovtseva L.S., Emelyanov I.V., Sviryaev Yu.V. Primary aldosteronism and resistant arterial hypertension. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2012;18(6):514-521. (In Russ.) https://doi.org/10.18705/1607-419X-2012-18-6-514-521
Просмотров:
1103
Послать статью по эл. почте 